article · Frontiers in Cellular and Infection Microbiology
The Gram-positive bacterium, <i>Filifactor alocis</i> is an oral pathogen, and approximately 50% of known strains encode a recently identified repeat-in-toxin (RTX) protein, FtxA. By assessing a longitudinal Ghanaian study population of adolescents (10-19 years of age; mean age 13.2 years), we recently discovered a possible correlation between deep periodontal pockets measured at the two-year follow-up, presence of the <i>ftxA</i> gene, and a high quantity of <i>F. alocis</i>. To further understand the contribution of <i>F. alocis</i> and FtxA in periodontal disease, we used qPCR in the present study to assess the carriage loads of <i>F. alocis</i> and the prevalence of its <i>ftxA</i> gene in subgingival plaque specimens, sampled at baseline from the Ghanaian cohort (n=500). Comparing these results with the recorded clinical attachment loss (CAL) longitudinal progression data from the two-year follow up, we concluded that carriers of <i>ftxA</i>-positive <i>F. alocis</i> typically exhibited higher loads of the bacterium. Moreover, high carriage loads of <i>F. alocis</i> and concomitant presence of the <i>ftxA</i> gene were two factors that were both associated with an enhanced prevalence of CAL progression. Interestingly, CAL progression appeared to be further promoted upon the simultaneous presence of <i>F. alocis</i> and the non-JP2 genotype of <i>Aggregatibacter actinomycetemcomitans</i>. Taken together, our present findings are consistent with the notion that <i>F. alocis</i> and its <i>ftxA</i> gene promotes CAL during periodontal disease.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3389/fcimb.2024.1376358
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.